

# SHARED CARE AGREEMENT



|                         |                                                                                                                                                     |
|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Name of medicine</b> | Aztreonam lysine (Cayston®) for nebulisation                                                                                                        |
| <b>Indication</b>       | Suppressive therapy of chronic pulmonary infections due to <i>Pseudomonas aeruginosa</i> in patients with cystic fibrosis aged six years and older. |

Version: **3.0**

Approval date: **June 2022**

Review date: **June 2025**

The Shared Care Agreement (SCA) is intended to facilitate the accessibility and safe prescribing of complex treatments across the secondary/primary care interface. It does not contain all of the relevant product information, which should be sought using the current British National Formulary and manufacturer's Summary of Product Characteristics. The SCA must be used in conjunction with the NHS Lothian Procedure for the Shared Care of Medicines, available [here](#).

## Roles and responsibilities

Listed below are specific responsibilities that are additional to those included in the NHS Lothian Policy and Procedures for Shared Care. Please refer to the policy for core roles and responsibilities that apply to all Shared Care Agreements.

### Consultant

- Initiating and supplying the first 28 days of treatment
- Training of patient/carer in the use of the medicine
- Promoting patient compliance/ adherence
- Checking baseline renal function and the annual checks thereafter
- Lung function assessment pre- and post- first dose to check for bronchospasm and ongoing monitoring of clinical parameters including lung function

### General Practitioner

- Prescribing after first 28 days of treatment in addition to the standard responsibilities listed in NHS Lothian 'Policy and Procedures for the Shared Care of Medicines'

### Patient, Relatives, Carers

As listed in NHS Lothian Policy and Procedures for the Shared Care of Medicines

## Support and Advice for the GP and primary care non-medical prescribers

### Contact Points (Paediatrics)

|                                                        |                                |
|--------------------------------------------------------|--------------------------------|
| CF secretaries for CF nurses and consultants           | Tel: 0131 312 0454             |
| Steve Cunningham, Consultant Respiratory Paediatrician |                                |
| Kenny MacLeod, Consultant Respiratory Paediatrician    |                                |
| Dr Don Urquhart, Consultant Paediatrician              |                                |
| Emilie Tennant, Senior Clinical Pharmacist             | Tel: 0131 312 0591 Bleep: 9156 |
| Carolyn Aitken-Arbuckle, CF Physiotherapist            | Tel: 0131 312 1047 Bleep: 9163 |
| Zoe Johnstone, CF Physiotherapist                      | Tel: 0131 312 1047 Bleep: 9163 |

### Contact Points (Adults)

|                                               |                    |
|-----------------------------------------------|--------------------|
| Specialist Cystic Fibrosis Nurses, WGH        | Tel: 0131 537 1783 |
| Dr Usma Koser, Consultant Physician, WGH      | Tel: 0131 537 1783 |
| Dr Robert Gray, Consultant Physician, WGH     | Tel: 0131 537 1783 |
| Dr Crichton Ramsay, Consultant Physician, WGH | Tel: 0131 537 1783 |
| Dr Helen Rodgers, Consultant Physician, WGH   | Tel: 0131 537 1783 |

*Shared Care Agreement: aztreonam lysine (Cayston®) for the suppressive therapy of chronic pulmonary infections due to *Pseudomonas aeruginosa* in patients with cystic fibrosis aged six years and older*

**Key Information on the Medicine**

Please refer to the current edition of the British National Formulary (BNF), available at [www.bnf.org](http://www.bnf.org), and Summary of Product Characteristics (SPC), available at [www.medicines.org.uk](http://www.medicines.org.uk) for detailed product and prescribing information and specific guidance.

**Background to disease and use of drug for the given indication**

Lung damage associated with persistent infection by *Pseudomonas aeruginosa* is the major cause of morbidity and mortality in people with cystic fibrosis (CF). Nebulised antipseudomonal antibiotic treatment controls the burden of infection and has been shown in randomised controlled trials to improve lung function, slow the rate of respiratory decline and reduce the frequency of exacerbations of infection. This reduces the need for intravenous antibiotic treatment, admission and the subsequent risk of developing antibiotic-related toxicity.

**Indication**

Suppressive therapy of chronic pulmonary infections due to *Pseudomonas aeruginosa* in patients with cystic fibrosis aged six years and older.

**Dosage and Administration**

Please refer to [www.bnf.org](http://www.bnf.org) and [www.medicines.org.uk](http://www.medicines.org.uk)

**Monitoring**

There are no specific monitoring requirements for the GP. All monitoring will be carried out by the CF clinics.

**Adverse effects** - Refer to current Summary of Product Characteristics (SPC): [www.medicines.org.uk](http://www.medicines.org.uk)

**Cautions and Contra-indications** - Refer to current Summary of Product Characteristics (SPC): [www.medicines.org.uk](http://www.medicines.org.uk)

**Drug interactions** - Refer to current Summary of Product Characteristics (SPC): [www.medicines.org.uk](http://www.medicines.org.uk)

The presence of this SCA does not compel a primary care prescriber to prescribe if they feel that it is out with the scope of their competencies (as per GMC guidance on safe prescribing) or resources, as ultimate responsibility lies with the prescribing, not the recommending, clinician.

Approved by the General Practice Prescribing Committee (GPPC) on 7<sup>th</sup> June 2022